200 related articles for article (PubMed ID: 21501547)
1. PSA and the family physician.
Barkin J
Can J Urol; 2011 Apr; 18 Suppl():20-3. PubMed ID: 21501547
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
Bunting PS; Goel V; Williams JI; Iscoe NA
CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen best practice statement: 2009 update.
Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P
J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
Kell JS
Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
[TBL] [Abstract][Full Text] [Related]
5. [Advancements in PSA-based screening for prostate cancer].
Ito K
Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
7. [Screening for early detection of prostate cancer (first experience in Israel)].
Neheman A; Shotland Y; Metz Y; Stein A
Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
Ito K
Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
[TBL] [Abstract][Full Text] [Related]
9. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
Nutahara K; Higashihara E
Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
[TBL] [Abstract][Full Text] [Related]
10. [Prostate cancer and prostate specific antigen screening].
Camici M
Minerva Med; 2004 Feb; 95(1):25-34. PubMed ID: 15041924
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
12. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
O'Dell KJ; Volk RJ; Cass AR; Spann SJ
J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
[TBL] [Abstract][Full Text] [Related]
14. [Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma].
Recker F
Schweiz Med Wochenschr; 1996 Nov; 126(44):1881-90. PubMed ID: 8984601
[TBL] [Abstract][Full Text] [Related]
15. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
16. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.
Jønler M; Eddy B; Poulsen J
Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era.
Platz EA; De Marzo AM; Giovannucci E
J Cell Biochem; 2004 Feb; 91(3):553-71. PubMed ID: 14755685
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
20. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
